{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T08:59:38Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 25.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094d6-def9-7fd1-b232-e22418fc04b7\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: cytostatic agent\nSense to describe: (none recorded)\nDomain code: PHY.OBJ\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 100", "usd": 0.0, "recall": true }, "codex": { "seconds": 73.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094d6-deee-7281-8f41-c73948eec572\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: cytostatic agent\nRegistry id: vr.tr.cytostatic-agent\nPlane / domain: PHY / PHY.OBJ\nRegistry definition: (none recorded)\nNames folded into this entry:" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:54:00+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:28+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q2140638", "registryId": "vr.tr.cytostatic-agent", "name": "cytostatic agent", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.OBJ" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q2140638/", "model": { "registry_id": "vr.tr.cytostatic-agent", "name": "cytostatic agent", "purpose": "Enable an AI agent to recognise a cytostatic agent, assess evidence that it inhibits cell proliferation, and identify the conditions and constraints governing its handling and use.", "definition": "A cytostatic agent is a substance that inhibits cell proliferation by slowing or arresting cell-cycle progression, without necessarily killing the affected cells.", "scope_statement": "This model owns the registered kind vr.tr.cytostatic-agent in PHY / PHY.OBJ: substances characterised by inhibition of cell proliferation, including their material identity, context-dependent activity, preparation state, and handling constraints; it does not equate cytostatic activity with a particular therapeutic indication.", "in_scope": [ "Substance identity and evidence supporting classification as a cytostatic agent", "Mechanism and cellular context of proliferation inhibition", "Concentration, exposure duration, and reversibility of observed effects", "Selectivity and distinction between proliferation inhibition and cell death", "Preparation, stability, containment, and disposal requirements" ], "out_of_scope": [ "Patient-specific treatment selection, prescribing, and dosing", "Cancer and other disease models", "Complete treatment regimens and interactions among their components", "Manufacturing facilities and administration devices", "Cell-culture and assay protocols as independently managed procedures", "Commercial medicinal products and individual stock containers as separate entities" ], "distinguishing_features": [ "Classification requires evidence of inhibited cell proliferation in a stated biological and exposure context; a therapeutic label alone is insufficient.", "A claim of cytostatic activity must distinguish reduced proliferation from loss of viable cells rather than infer arrest solely from a lower cell count.", "Cytostatic and cytotoxic effects must be recordable together when their balance changes with concentration, exposure duration, or cell population.", "The entry represents a functional class of substances, while named compounds, marketed formulations, and individual samples require separate identities.", "Anticancer use, cell-cycle target engagement, or an antimicrobial effect alone does not establish the particular cytostatic activity being claimed." ], "characteristics": [ { "name": "Substance identity", "kind": "relation", "unit_or_values": "Links to identified active substances, chemical forms, and authoritative identity records", "why_it_matters": "Prevents evidence for one compound or chemical form from being assigned to another." }, { "name": "Classification basis", "kind": "category", "unit_or_values": "Observed proliferation inhibition; reported class membership; unresolved", "why_it_matters": "Separates measured activity from terminology inherited from a source." }, { "name": "Biological test context", "kind": "relation", "unit_or_values": "Cell population, species, tissue origin, culture or organism context, and relevant molecular features", "why_it_matters": "Cytostatic activity cannot be interpreted independently of the system in which it was observed." }, { "name": "Exposure concentration", "kind": "measurement", "unit_or_values": "mol/L or mass/volume, with chemical form and nominal or measured status", "why_it_matters": "Defines the exposure associated with inhibition and supports qualified comparisons." }, { "name": "Exposure duration", "kind": "measurement", "unit_or_values": "Hours or days, including continuous, pulsed, and washout intervals", "why_it_matters": "Distinguishes transient inhibition from effects that persist after exposure." }, { "name": "Proliferation response", "kind": "measurement", "unit_or_values": "Assay-defined growth rate, division count, or percentage inhibition relative to a specified control", "why_it_matters": "Records the defining effect without treating unlike endpoints as interchangeable." }, { "name": "Concurrent viability response", "kind": "measurement", "unit_or_values": "Viable-cell fraction or death-associated endpoint, with method and observation time", "why_it_matters": "Helps separate proliferation inhibition from cytotoxicity." }, { "name": "Recovery after withdrawal", "kind": "state", "unit_or_values": "Proliferation resumes; inhibition persists over observation period; mixed response; untested", "why_it_matters": "Makes reversibility an observed property rather than an assumed defining feature." }, { "name": "Mechanistic attribution", "kind": "relation", "unit_or_values": "Supported links to molecular targets, pathways, and cell-cycle effects", "why_it_matters": "Connects the observed phenotype to an explanation while retaining evidence limits." }, { "name": "Preparation suitability", "kind": "state", "unit_or_values": "Meets specified preparation criteria; degraded; precipitated; contaminated; expired under applicable specification; unknown", "why_it_matters": "Determines whether material condition supports interpretation or authorised use." }, { "name": "Handling classification", "kind": "relation", "unit_or_values": "Applicable safety data sheet, hazard assessment, containment requirements, and waste rules", "why_it_matters": "Grounds handling decisions in the actual substance and preparation." } ], "affordances": [ "Assess whether a substance qualifies as cytostatic within a documented biological context.", "Compare proliferation responses when exposure conditions, controls, and endpoints are sufficiently aligned.", "Identify evidence needed to distinguish growth inhibition from cell death.", "Trace a claimed mechanism to supporting experiments and record competing explanations.", "Check a preparation against substance-specific stability and handling requirements.", "Route proposed use, transfer, or disposal through the applicable protocol and responsible authority." ], "agent_conduct": { "may": [ "Explain what cytostatic agents are and how they differ from cytotoxic drugs, from reliable sources.", "Report safe handling requirements from official guidance and product labelling.", "Track stock and handling records in a pharmacy the agent is authorized to manage." ], "must_not": [ "Recommend, dose or adjust a cytostatic agent for a particular patient.", "Handle or dispose of these drugs outside the site's hazardous drug procedures.", "Promote unproven substances as cytostatic cancer cures.", "Disclose a person's cancer treatment without consent." ], "requires_human": [ "Any prescribing or treatment decision.", "Responding to a spill of a hazardous drug." ] }, "ethics": { "considerations": [ "Cancer patients need accurate information and protection from false cures.", "Health workers who handle these drugs can be harmed by repeated exposure." ], "affected_parties": [ "Patients", "Nurses and pharmacists", "Families and carers" ] }, "owners": { "steward": "The prescribing clinician for each use; medicines regulators authorize products.", "master_systems": [ "National medicines registers" ] }, "failure_modes_and_hazards": [ "Can suppress the immune system and harm a developing fetus.", "Occupational exposure needs protective handling." ], "what_it_is_for": [ "Cytostatic drugs are encountered in clinical treatment and biomedical research where inhibition of cell proliferation is an intended effect.", "The term describes a biological effect across different substances, so interpretation depends on the particular drug, target cells and evidence." ], "standards_and_regulation": [ "Directive 2001/83/EC, adopted by the European Parliament and the Council of the European Union, establishes the Community code relating to medicinal products for human use and applies to cytostatic medicines within its scope.", "The Federal Food, Drug, and Cosmetic Act, enacted by the United States Congress, governs human drugs including cytostatic medicines marketed in the United States." ], "facets_not_applicable": { "recognition": "Cytostatic activity is a biological effect that cannot be established from a substance's appearance or dosage form." } }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q2140638: cytostatic agent", "url": "https://www.wikidata.org/wiki/Q2140638", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Cytostatic agent", "url": "https://en.wikipedia.org/wiki/Cytostatic_agent", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity and classification", "description": "Establishes which substances this functional class includes and on what evidence.", "rationale": "The registry supplies no definition, and class terminology must not substitute for a demonstrated biological effect.", "layers": [ { "id": "class-boundary", "name": "Class boundary", "description": "Defines the intended meaning of cytostatic agent and its neighbouring classes.", "findings": [ { "id": "cytostatic-membership", "name": "Cytostatic membership", "description": "Record the working definition and the evidence required to classify a substance under it.", "questions": [ { "text": "Does this registry entry cover any substance with demonstrated cytostatic activity or a narrower medicinal class?", "kind": "definition", "id": "cytostatic-membership-q01" }, { "text": "What evidence distinguishes membership here from cytotoxic-agent or antineoplastic-agent classification?", "kind": "boundary", "id": "cytostatic-membership-q02" } ] } ] }, { "id": "active-substance-resolution", "name": "Active substance resolution", "description": "Connects class membership to the material actually studied.", "findings": [ { "id": "tested-material-identity", "name": "Tested material identity", "description": "Record whether activity belongs to a specified compound, chemical form, mixture, or biologically generated active species.", "questions": [ { "text": "Which identified substance and chemical form were present in the reported experiment?", "kind": "provenance", "id": "tested-material-identity-q01" }, { "text": "Was activity attributed to the supplied substance, an active metabolite, or an unresolved component?", "kind": "boundary", "id": "tested-material-identity-q02" } ] } ] } ] }, { "id": "mechanism-and-cellular-context", "name": "Mechanism and cellular context", "description": "Relates proliferation inhibition to cellular processes and biological dependencies.", "rationale": "An agent's cytostatic effect may depend on the cell population and cannot be inferred from target identity alone.", "layers": [ { "id": "mechanistic-support", "name": "Mechanistic support", "description": "Separates observed inhibition from proposed causal explanations.", "findings": [ { "id": "target-to-arrest-evidence", "name": "Target-to-arrest evidence", "description": "Record evidence connecting target engagement or pathway modulation to reduced cell division.", "questions": [ { "text": "Which experiments connect the proposed molecular action to proliferation inhibition?", "kind": "provenance", "id": "target-to-arrest-evidence-q01" }, { "text": "What cell-cycle distribution or division-tracking result supports the proposed arrest mechanism?", "kind": "measurement", "id": "target-to-arrest-evidence-q02" } ] } ] }, { "id": "response-dependencies", "name": "Response dependencies", "description": "Captures the cellular features and conditions associated with activity.", "findings": [ { "id": "responsive-cell-context", "name": "Responsive cell context", "description": "Record tested populations, their proliferative state, and supported sensitivity or resistance factors.", "questions": [ { "text": "Which cell populations and baseline proliferative states were tested?", "kind": "provenance", "id": "responsive-cell-context-q01" }, { "text": "Which molecular or environmental features were demonstrated to alter the response?", "kind": "measurement", "id": "responsive-cell-context-q02" } ] } ] } ] }, { "id": "exposure-and-effect-evidence", "name": "Exposure and effect evidence", "description": "Defines how cytostatic activity was measured and how it changes with exposure.", "rationale": "A proliferation claim requires interpretable endpoints, controls, concentrations, and observation periods.", "layers": [ { "id": "proliferation-measurement", "name": "Proliferation measurement", "description": "Makes activity measurements interpretable and comparable.", "findings": [ { "id": "growth-inhibition-endpoint", "name": "Growth inhibition endpoint", "description": "Record the assay endpoint, baseline, controls, exposure conditions, and uncertainty supporting an inhibition claim.", "questions": [ { "text": "What endpoint measures proliferation, and how is it normalised to baseline and controls?", "kind": "measurement", "id": "growth-inhibition-endpoint-q01" }, { "text": "What concentrations, exposure durations, replicates, and uncertainty estimates accompany the result?", "kind": "measurement", "id": "growth-inhibition-endpoint-q02" } ] } ] }, { "id": "effect-persistence", "name": "Effect persistence", "description": "Tracks proliferation during exposure and after withdrawal.", "findings": [ { "id": "withdrawal-and-regrowth", "name": "Withdrawal and regrowth", "description": "Record recovery observations without assuming all cytostatic effects are reversible.", "questions": [ { "text": "Does proliferation resume after withdrawal, and over what observation interval?", "kind": "measurement", "id": "withdrawal-and-regrowth-q01" }, { "text": "What evidence distinguishes persistent arrest from residual exposure or delayed cell death?", "kind": "boundary", "id": "withdrawal-and-regrowth-q02" } ] } ] } ] }, { "id": "cytotoxicity-and-selectivity", "name": "Cytotoxicity and selectivity", "description": "Separates inhibited division from cell loss and qualifies claims of selective activity.", "rationale": "Reduced cell accumulation can have different causes, and selective activity requires explicit comparators.", "layers": [ { "id": "viability-discrimination", "name": "Viability discrimination", "description": "Pairs proliferation evidence with measurements of survival or death.", "findings": [ { "id": "arrest-versus-cell-loss", "name": "Arrest versus cell loss", "description": "Record whether the observed response reflects arrest, death, or a mixture at each relevant exposure.", "questions": [ { "text": "Which independent viability or death measurements accompany the proliferation endpoint?", "kind": "measurement", "id": "arrest-versus-cell-loss-q01" }, { "text": "Under which tested conditions does the response shift between predominantly cytostatic and predominantly cytotoxic?", "kind": "boundary", "id": "arrest-versus-cell-loss-q02" } ] } ] }, { "id": "comparative-selectivity", "name": "Comparative selectivity", "description": "Limits selectivity claims to the populations and conditions actually compared.", "findings": [ { "id": "selectivity-comparator", "name": "Selectivity comparator", "description": "Record comparative effects on intended target populations and relevant non-target populations.", "questions": [ { "text": "Which target and non-target populations were compared under matched exposure conditions?", "kind": "provenance", "id": "selectivity-comparator-q01" }, { "text": "How were differences in baseline division rate addressed when interpreting apparent selectivity?", "kind": "measurement", "id": "selectivity-comparator-q02" } ] } ] } ] }, { "id": "preparation-and-controlled-handling", "name": "Preparation and controlled handling", "description": "Connects biological interpretation and permissible actions to the actual preparation and its documented hazards.", "rationale": "Preparation changes can affect exposure, while handling requirements must come from substance-specific evidence.", "layers": [ { "id": "exposure-material-quality", "name": "Exposure material quality", "description": "Records preparation properties that influence delivered concentration and activity.", "findings": [ { "id": "preparation-integrity", "name": "Preparation integrity", "description": "Track solvent, concentration, storage history, and evidence of stability or incompatibility relevant to the intended context.", "questions": [ { "text": "What preparation and stability evidence supports the stated concentration during use?", "kind": "provenance", "id": "preparation-integrity-q01" }, { "text": "Which observed or documented conditions require the preparation to be withheld, replaced, or reassessed?", "kind": "action", "id": "preparation-integrity-q02" } ] } ] }, { "id": "handling-and-disposition", "name": "Handling and disposition", "description": "Associates manipulation and waste actions with applicable documented requirements.", "findings": [ { "id": "substance-specific-controls", "name": "Substance-specific controls", "description": "Record relevant exposure routes, containment, spill response, and waste instructions for the identified preparation.", "questions": [ { "text": "Which current safety data sheet and local assessment govern this substance and preparation?", "kind": "provenance", "id": "substance-specific-controls-q01" }, { "text": "What controls and authorised procedures apply to preparation, transfer, spills, and disposal?", "kind": "action", "id": "substance-specific-controls-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Check whether the registry intends the strict growth-arrest sense or the broader clinical synonym for anticancer drugs.", "The listed kinds overlap and are mechanism-based groupings, not a mutually exclusive classification.", "Specific hazards, effective concentrations, and regulatory requirements require identification of the substance, formulation, and intended use." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of cytostatic agent this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Cyclin-dependent kinase inhibitors", "Antimetabolites with cytostatic effects", "Hormonal agents that suppress hormone-dependent cell proliferation", "Signal-transduction inhibitors with cytostatic effects" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of cytostatic agent this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "Individual substances have identifiers formatted as digits-digits-check digit.", "note": "Cytostatic agent is a functional category, not a single substance with one CAS number." }, { "scheme": "WHO Anatomical Therapeutic Chemical classification", "value_or_pattern": "L01; L02", "note": "Antineoplastic agents and endocrine therapy, respectively; these categories include relevant medicines but are not equivalent to cytostatic agents." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of cytostatic agent this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Suppressing tumour-cell proliferation in cancer treatment", "Suppressing immune-cell proliferation with selected agents in immunosuppressive treatment", "Experimentally studying cell-cycle regulation and growth arrest" ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of cytostatic agent this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "GI50, the concentration producing 50% growth inhibition relative to an assay control", "typical_range": "Agent-, cell-system-, and exposure-dependent; no class-wide range", "unit": "mol/L" }, { "quantity": "Fraction of cells in a specified cell-cycle phase", "typical_range": "Assay- and treatment-dependent", "unit": "%" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of cytostatic agent this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Intrinsic or acquired resistance can allow proliferation to continue.", "Cells may resume proliferation after treatment is withdrawn.", "Effects on normal proliferating cells can cause toxicity, including bone-marrow suppression or mucosal injury, depending on the agent.", "Some agents have reproductive, developmental, genotoxic, or carcinogenic hazards; these cannot be inferred uniformly from the category.", "Reduced cell numbers in an assay can reflect cell killing rather than growth arrest, causing misclassification of the effect." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of cytostatic agent this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Some clinical and occupational usage applies the term cytostatics broadly to anticancer medicines, including agents with substantial cytotoxic effects." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of cytostatic agent this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Cytotoxic agent", "difference": "Cytotoxicity denotes cell damage or death; cytostasis denotes inhibited proliferation. One substance can produce both, depending on exposure and cell type." }, { "name": "Antineoplastic agent", "difference": "Defined by activity against neoplasms; a cytostatic agent is defined by its effect on cell proliferation." }, { "name": "Antimitotic agent", "difference": "Interferes specifically with mitosis; cytostatic activity can act at other stages or through other growth-regulating processes." }, { "name": "Immunosuppressant", "difference": "Suppresses immune function; only some immunosuppressants do so by inhibiting cell proliferation." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of cytostatic agent this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does the registry intend a broad functional class of proliferation-inhibiting substances or the narrower usage found in particular medicinal classifications?", "Does an existing Vercy world model already own this concept, requiring the registry entry to link to it?", "Which authoritative sources should establish the working definition and resolve overlap with cytotoxic and antineoplastic terminology?", "What minimum combination of proliferation, viability, and recovery evidence should support a cytostatic classification?", "How should evidence for metabolites, mixtures, and formulations be linked without incorrectly transferring activity to every associated substance?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }